TREX1 基因突变及其在系统性红斑狼疮中的作用
TREX1基因突变及其在系统性红斑狼疮中的作用:一项基因型-表型相关性研究
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by diverse clinical manifestations, prominently involving the skin.
研究概览
详细说明
Cutaneous lesions are among the earliest and most frequent features of SLE, with over 70% of patients developing mucocutaneous involvement during their disease course.
The presence and severity of cutaneous manifestations have been associated with specific autoantibodies, such as anti-Ro/SSA and anti-dsDNA, which may reflect underlying genetic susceptibility.
Recent studies have also implicated gene polymorphisms in IRF5, STAT4, TREX1, and TNFA in the pathogenesis of cutaneous SLE phenotypes.
Defective TREX1 exonuclease activity, leading to intracellular accumulation of DNA, may trigger type I interferon activation-a key mechanism in lupus pathophysiology.
Despite the extensive global literature, data from Egyptian patients remain limited, especially regarding the relationship between TREX1 gene variants and cutaneous lupus phenotypes.
Understanding how autoantibody profiles and gene polymorphisms relate to clinical features and disease activity could enhance early diagnosis, predict flares, and improve personalized therapy.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
South Valley
-
Qina、South Valley、埃及
- Qina University hospital, South Valley University Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
- Group A: 60 adults (18-60 years) diagnosed with SLE based on 2019 EULAR/ACR criteria, each with at least one cutaneous manifestation.
- Group B: 30 age- and sex-matched healthy controls with no personal or family history of autoimmune disease and negative ANA and anti-dsDNA.
描述
Inclusion Criteria:
- Adult aged 18-60 years
- Diagnosed as SLE per 2019 EULAR/ACR classification criteria.
- Presence of at least one cutaneous manifestation (acute, subacute, or chronic).
- Willing to provide written informed consent for participation and genetic testing
Exclusion Criteria:
- Overlap autoimmune syndromes (e.g., dermatomyositis, systemic sclerosis).
- Systemic infection, malignancy, or pregnancy.
- Use of biologic therapy or immunosuppressive pulses within one month.
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Group A : (Systemic Lupus Erythrematosus)
About 90 patients diagnosed with SLE based on 2019 EULAR/ACR criteria, each with at least one cutaneous manifestation. |
To assess the prevalence of selected autoantibodies as (anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB) and TREX1 gene polymorphisms in SLE patients, and their association with clinical features and disease activity
其他名称:
|
|
Group B (Healthy Controls)
90 age- and sex-matched healthy controls with no personal or family history of autoimmune disease and negative ANA and anti-dsDNA. |
To assess the prevalence of selected autoantibodies as (anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB) and TREX1 gene polymorphisms in SLE patients, and their association with clinical features and disease activity
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Systemic Lupus Erythematosus Assessment
大体时间:3 Months
|
Assessment of disease activity in Systemic Lupus Erythematosus (SLE) using Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). SLEDAI-2K as follows : 1-5 is Mild disease activity 6-10 is Moderate disease activity 11 or more is Severe disease activity |
3 Months
|
|
TREX1 gene polymorphism and SLE
大体时间:3 Months
|
Assessment the association between TREX1 gene polymorphism and systemic lupus erythematosus susceptibility |
3 Months
|
合作者和调查者
调查人员
- 学习椅:Eisa Mohammed Hegazy, Professor、Dermatology, Venereology and Andrology. Faculty of Medicine,Qena University
- 研究主任:Mohammed Hosny Hassan, Professor、Biochemistry ,Qena faculty of medicine ,south valley university
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.